BioPharmSignal logoBioPharmSignal

Biotech News

Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference

Lucid Diagnostics (LUCD)Lucid DiagnosticsConference / presentation

LUCD (LUCD) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is lucd.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

LUCDLucid Diagnostics2026-08-04 12:30 EST

Lucid Diagnostics to Participate in Upcoming Investor Conferences

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

LUCDLucid Diagnostics2026-08-05 12:46 EST

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

LYELLyell Immunopharma2026-06-01 12:00 EST

Lyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026

LYELLyell Immunopharma2026-06-25 12:00 EST

Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

COGTCogent Biosciences2026-06-12 12:01 EST

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

View all latest news

Lucid Diagnostics

Esophageal Cancer Prevention Company Lucid Diagnostics is a commercial-stage diagnostics subsidiary of PAVmed focused on detecting esophageal precancer in patients with chronic gastroesophageal reflux disease. EsoGuard and EsoCheck The EsoGuard DNA test is performed on samples collected with the non-endoscopic EsoCheck cell-collection...

Recent company news

LUCDLucid Diagnostics2026-08-05 12:46 EST

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard® Esophageal DNA Test

LUCDLucid Diagnostics2026-08-04 12:30 EST

Lucid Diagnostics to Participate in Upcoming Investor Conferences

LUCDLucid Diagnostics2026-07-30 12:30 EST

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

LUCDLucid Diagnostics2026-05-14 12:00 EST

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

LUCDLucid Diagnostics2026-04-30 12:31 EST

Lucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026

Stock data

Close
0.95 USD
Market cap
196.48M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States